Middle East and Africa Acute Coronary Syndrome Market – Industry Trends and Forecast to 2029

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Middle East and Africa Acute Coronary Syndrome Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Published Report
  • Mar 2022
  • MEA
  • 350 Pages
  • No of Tables: 44
  • No of Figures: 35

Middle East and Africa Acute Coronary Syndrome Market, By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others)- Industry Trends and Forecast to 2029.

Middle East and Africa Acute Coronary Syndrome Market

Middle East and Africa Acute Coronary Syndrome Market Analysis and Insights

Middle East and Africa acute coronary syndrome market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 3.9% in the forecast period of 2022 to 2029 and is expected to reach USD 266.77 million by 2029. The major factors driving the growth of the Middle East and Africa acute coronary syndrome market are rise in prevalence of chronic diseases, such as coronary artery disease, ischemic heart disease, and vascular diseases, growing geriatric population, wide range of products offered by market players leading the acute coronary syndrome market to grow in future.

Middle East and Africa Acute Coronary Syndrome Market

Middle East and Africa Acute Coronary Syndrome Market

Acute coronary syndrome refers to a group of diseases in which blood flow to the heart decreases. Conditions related to ACS include ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. It is a type of Coronary Heart Disease (CHD), which is responsible for one-third of total deaths in people older than 35. Some forms of CHD can be asymptomatic, but ACS is always symptomatic.

Acute coronary syndrome (ACS) is a manifestation of coronary heart disease (CHD) and usually a result of plaque disruption in coronary arteries (atherosclerosis). The common risk factors for the disease are smoking, hypertension, diabetes, hyperlipidemia, physical inactivity, family obesity, and poor nutritional practices. Cocaine abuse can also lead to vasospasm. A family history of early myocardial infarction (55 years of age) is also a high-risk factor.

The Middle East and Africa acute coronary syndrome market report provides details of market share, new developments, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, products approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

By Type (Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, and Unstable Angina), Diagnosis (Stress Test, Blood Tests, Imaging and Others), Treatment (Medication and Surgery), End User (Hospitals and Clinics, Diagnostic Centers, Academic Institutes and Others)

Countries Covered

South Africa, Saudi Arabia, U.A.E, Egypt, Israel and Rest of Middle East and Africa.

Market Players Covered

AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others.

Acute Coronary Syndrome Market Dynamics

Drivers

  • Rise in Prevalence of Chronic Diseases, such as Coronary Artery Disease, Ischemic Heart Disease, and Vascular Diseases

As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the U.S., Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of acute coronary syndrome boosts the market growth.

  • Growing Geriatric Population

The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in Middle East and Africa& Asia-Pacific region, creates an opportunity for market growth in the forecast period.

  • Wide Range of Products Offered by Market Players

Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions. This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.

Opportunities

As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the Middle East and Africa coronary syndrome market in the forecast period.

Also, Governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.

Restraints/Challenges

Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are the restrains and challenges for the growth of acute coronary syndrome market.

The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of these product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.

This acute coronary syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on acute coronary syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In November 2021, Merck, announced the successful completion of the acquisition of Acceleron Pharma Inc. It is an important and strategic opportunity for company to continue growing their cardiovascular portfolio and pipeline that builds on long and proud legacy in cardiovascular disease and further bolsters company’s business development strategy fueled by Acceleron’s groundbreaking research.

Middle East and Africa Acute Coronary Syndrome Market Scope

Middle East and Africa acute coronary syndrome market is categorized based on type, treatment, diagnosis and end user. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

  • Non-St-Elevation Myocardial Infarction
  • St-Elevation Myocardial Infarction
  • Unstable Angina

On the basis of type, the Middle East and Africa acute coronary syndrome market is segmented into non-St-elevation myocardial infarction, St-elevation myocardial infarction and unstable angina.

Diagnosis

  • Stress Test
  • Blood Tests
  • Imaging
  • Others

On the basis of diagnosis, the Middle East and Africa acute coronary syndrome market is segmented into stress test, blood test, imagining and others.

Treatment

  • Medication
  • Surgery

On the basis of treatment, the Middle East and Africa acute coronary syndrome market is segmented into medication and surgery.

End User

  • Hospitals and Clinics
  • Diagnostic Centers
  • Academic Institutes
  • Others

Middle East and Africa Acute Coronary Syndrome Market

On the basis of end user, the Middle East and Africa acute coronary syndrome market is segmented into hospitals and clinics, diagnostic centers, academic institutes and others.

Acute Coronary Syndrome Market Regional Analysis/Insights

Middle East and Africa acute coronary syndrome market is further segmented into major countries including South Africa, Saudi Arabia, U.A.E, Egypt, Israel and Rest of Middle East and Africa.

South Africa in Middle East and Africa dominates the acute coronary market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the well-developed healthcare infrastructure in the country.

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Acute Coronary Syndrome Market Share Analysis

Middle East and Africa acute coronary syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acute coronary syndrome market.

Some of the prominent participants operating in the Middle East and Africa acute coronary syndrome market are Movianto (U.S.), Sharp (U.S.),Thermo Fisher Scientific Inc.,(U.S.), Catalent, Inc (U.S.), PCI Pharma Services (U.S.), Almac Group (U.K.), PAREXEL International Corporation (U.S.), Bionical Ltd. (U.K.), Alium Medical Limited (U.K.), MYODERM (U.K.), Clinigen Group plc (U.K.), Ancillare, LP (U.S.), SIRO Clinpharm (India) CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC. (U.S.) Biocair (U.K.) and others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analysed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, GlobalVsRegional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 SERVICES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES, SUCH AS CORONARY ARTERY DISEASE, ISCHEMIC HEART DISEASE, AND VASCULAR DISEASES

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 WIDE RANGE OF PRODUCTS OFFERED BY MARKET PLAYERS

6.1.4 IMPROVING HEALTHCARE INFRASTRUCTURE AND REIMBURSEMENT POLICIES

6.2 RESTRAINTS

6.2.1 RISE IN COST OF THERAPEUTIC SURGERY

6.2.2 STRINGENT RULES & REGULATIONS

6.3 OPPORTUNITIES

6.3.1 SURGE IN TECHNOLOGICAL ADVANCEMENTS FOR CARDIOVASCULAR DISEASE

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 INCREASED REIMBURSEMENT POLICIES

6.3.4 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF ACCESSIBILITY OF SERVICES

6.4.2 LONG PROCESS OF APPROVAL BY REGULATORY BODIES

7 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TYPE

7.1 OVERVIEW

7.2 NON-ST- ELEVATION MYOCARDIAL INFARCTION

7.3 ST-ELEVATION MYOCARDIAL INFARCTION

7.4 UNSTABLE ANGINA

8 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS

8.1 OVERVIEW

8.2 STRESS TEST

8.3 BLOOD TEST

8.4 IMAGING

8.5 OTHERS

9 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 MEDICATION

9.3 SURGERY

10 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS AND CLINICS

10.3 DIAGNOSTIC CENTERS

10.4 ACADEMIC INSTITUTES

10.5 OTHERS

11 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY REGION

11.1 MIDDLE EAST & AFRICA

11.1.1 SOUTH AFRICA

11.1.2 SAUDI ARABIA

11.1.3 UAE

11.1.4 EGYPT

11.1.5 ISRAEL

11.1.6 REST OF MIDDLE EAST & AFRICA

12 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 NOVARTIS AG

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.1.5.1 PRODUCT EXPANSION

14.1.5.2 COLLABRATION

14.2 ASTRA ZENECA

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT

14.2.5.1 ACQUISITION

14.3 AMGEN INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 SANOFI

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.4.5.1 ACQUISITION

14.5 BAXTER

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 DR. REDDY’S LABORATORIES LTD.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.6.4.1 ACQUISTION

14.7 PFIZER INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 MERCK & CO., INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.8.4.1 EVENT

14.8.4.2 ACQUISTION

14.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.9.3.1 PRODUCT APPROVAL

14.1 CSL

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENT

14.10.4.1 ACQUISITION

14.11 DAIICHI SANKYO COMPANY,LIMITED

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.11.4.1 PARTNERSHIP

14.12 JOHNSON & JOHNSON SERVICES, INC.

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENT

14.12.4.1 ACQUISITION

14.13 TEVA PHARMACEUTICAL INDUSTRIES LTD.

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT

14.13.4.1 ACQUISITION

14.14 REGENERON PHARMACEUTICALS INC.

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 LIST OF RECENT PROGRESS OF 3D BIO PRINTING FOR CARDIAC TISSUE ENGINEERING-

TABLE 2 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA NON-ST-ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA ST—ELEVATION MYOCARDIAL INFARCTION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA UNSTABLE ANGINA IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA STRESS TEST IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA BLOOD TEST IN ACUTE SYNDROME CORONARY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA IMAGING IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA MEDICATION IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA SURGERY IN ACUTE CORONARY SYNDROME MARKET, BY REGION 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ACADEMIC INSTITUTES IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA OTHERS IN ACUTE CORONARY SYNDROME MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 24 SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 25 SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 26 SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 27 SOUTH AFRICA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029,(USD MILLION)

TABLE 29 SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 30 SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 31 SAUDI ARABIA ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 32 UAE ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 33 UAE ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 34 UAE ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 35 UAE ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 36 EGYPT ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 37 EGYPT ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 38 EGYPT ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 39 EGYPT ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 ISRAEL ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 41 ISRAEL ACUTE CORONARY SYNDROME MARKET, BY DIAGNOSIS, 2020-2029 (USD MILLION)

TABLE 42 ISRAEL ACUTE CORONARY SYNDROME MARKET, BY TREATMENT, 2020-2029 (USD MILLION)

TABLE 43 ISRAEL ACUTE CORONARY SYNDROME MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 44 REST OF MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA ACUTE CORONNARY SYNDROME MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: SEGMENTATION

FIGURE 10 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 11 RISING PREVALENCE OF CORONARY ARTERY DISEASE, ISCHEMIC HEART AND VASCULAR DISEASE AS WELL AS GROWING GERIATRIC POPULATION IS DRIVING THE MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET

FIGURE 14 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2021

FIGURE 15 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2021

FIGURE 19 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2021

FIGURE 23 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY END USER, 2021

FIGURE 27 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: SNAPSHOT (2021)

FIGURE 31 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021)

FIGURE 32 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: BY TYPE (2022-2029)

FIGURE 35 MIDDLE EAST & AFRICA ACUTE CORONARY SYNDROME MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Middle East and Africa Acute Coronary Syndrome Market will be projected to grow at a CAGR of 3.9% during the forecast by 2029.
The Middle East and Africa Acute Coronary Syndrome Market will be projected at USD 266.77 million during the forecast by 2029.
The major players operating in the Middle East and Africa Acute Coronary Syndrome Market are AstraZeneca, Daiichi Sankyo company, Johnson & Johnson Service Inc., Amgen Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc, Sanofi, CSL Behring, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Baxter, Dr. Reddy’s Laboratories, Merck & Co., Inc. and Novartis AG and among others.
Rise in cost of the therapeutic surgery and lack of accessibility of disease management services and support in low economic countries are poised to restrict the Middle East and Africa Acute Coronary Syndrome Market growth.